



DOCKET NO. 1161.1027-064

## TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

In re Application of:

Maria S. Gawryl, Robert A. Houtchens and William R. Light

Application No.:

10/018,599

Filed (371(c)):

May 22, 2002

Confirmation No.:

8372

For:

PRESERVING A HEMOGLOBIN BLOOD SUBSTITUTE WITH A TRANSPARENT OVERWRAP

The owner. Biopure Corporation of 100 percent interest in the instant application hereby discluims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior Patent Nos. 6,288,027 and 6,271,351. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer in the event that it later: expires for fallure to pay a maintenance fac, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

The terminal disclaimer fee under 37 CFR 1.20(d) is enclosed.

The undersigned is empowered to act on behalf of the owner.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these attatements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may joopardize the validity of the application of any patent issued thereon.

1 April 05

Carl W. Rausch

Typed or printed name

Biopure Corporation



Docket No. 1161,1027-064

## STATEMENT UNDER 37 C.F.R. § 3.73(b)

Applie	ation N	o./Patont No.: 10/018,599	Filed (371(c)): May 22, 2002
For: <u>PR</u>	ESER	VING A HEMOGLOBIN BLOOD S	SUBSTITUTE WITH A TRANSPARENT OVERWRAP
		Biopure Corporation,	a <u>Corporation</u>
	hat it is	(Name of Anignes)	(Type of Assignee, e.g., corporation, partnership, university, government agency, suc.)
	[X]	.4	tale and the control of the control
Α.	. 1~1	ten assisting or the cutité tigut ti	tle and interest in the patent application identified above; or
3.	<b>L</b> 1	an assignce together with [ ubove.	] of the entire right, title and interest in the patent application identified
he rig	ht, title	and interest of the above-named assi	ignee in the patent application identified above is established by virtue of:
A. [X]	An as	signment from the inventor(s) of the rademark Office at Reel01292	patent application identified above. The assignment was recorded in the Puter 9. Frame 0553-0556, or a copy thereof is attached.
R			
3.[]	A chai	in of title from the inventor(s) of the	patent application identified above, to the current assignee as shown below:
• •			·
	1,	From: The document was recorded in the	To:  United States Patent and Trademark Office at
			or a copy thereof is attached.
	2.	From:	То:
			a United States Patent and Trademark Office at
		Reel, Frame	, or a copy thereof is steached,
	3.	From:	To:
		The document was recorded in the	United States Patent and Trademark Office at
		Reel, Framo	, or a copy thereof is attached.
•	[ ] A	dditional documents in the chain of t	ditie are listed on a supplemental sheet.
be und	ersigned	i (whosوغنائة is supplied below) is s	uthorized to act on behalf of the assigned,
	)		
enatur	e: /	I all let	(MURI)
<b>-</b>			The state of the s
ame:		Carl W. Rausch	
tle;		Cofounder and Vice Chairman and	Chief Technology Officer

@PPDetkipt:UDMA/MHODMA/HRRRUS(Minnge)\$370141